Health headlines today span prevention, innovation and public concern. In the UK, advisers have recommended offering the meningitis B vaccine to all 15-year-olds on the NHS, with catch-up doses for those who missed earlier protection, a move shaped by recent outbreaks and the deaths of two teenagers in Kent. In the US biotech sector, Eli Lilly is making a bold mental-health play, agreeing to buy psychedelics specialist AtaiBeckley in a deal worth up to $3.8 billion, signalling growing mainstream confidence in experimental neuroscience treatments. Elsewhere, health issues surfaced in unexpected places: an Indian consumer forum ruled that a Maruti Suzuki vehicle should be replaced or refunded after complaints it was not fit for widely available E20 fuel, underscoring the public-health overlap between regulation, disclosure and safety. And in a troubling family court case, concerns have been raised that two missing boys may be without schooling or medical care while hidden in the UK.